The trial is taking place at:

South Florida Research Institute | Lauderdale Lakes, FL

Veeva-enabled site

Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease


Inversago Pharma

Status and phase

Active, not recruiting
Phase 2


Diabetic Kidney Disease


Drug: Placebo
Drug: INV-202

Study type


Funder types




Details and patient eligibility


The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due to either Type 1 diabetes mellitus or Type 2 diabetes mellitus

Full description

This is a Phase 2, randomized, double-blind, placebo controlled, dose ranging, multicenter study designed to assess the efficacy, safety, tolerability, and pharmacokinetics of INV-202 for the treatment of adult participants with a diagnosis of DKD due to either Type 1 diabetes mellitus (T1DM) or Type 2 diabetes mellitus (T2DM) (diagnosed ≥1 year) who are on a stable anti diabetic medication regimen for ≥4 months prior with a HbA1c <9.5%. Approximately 240 participants (80/arm) will be randomized to 1 of 3 treatment arms in a 1:1:1 ratio: INV 202 10 mg, INV-202 25 mg, or placebo. The assigned study treatment will be taken once daily (QD), for 16 weeks. Due to the high expected screen failure rates, participants may be pre-screened at sites with an approved pre-screening ICF. Each participant will be allowed 1 retest during the screening period if they fail screening and 1 re-screening on a case by case basis with approval from the Worldwide medical monitors. Study participation will last approximately 22 weeks and includes a Screening Period (up to 4 weeks), a Study Treatment Period with 16 weeks of daily study treatment, and a Safety Follow-Up Visit consisting of a phone call 2 weeks after the End of Treatment Visit (Week [W]18) to allow reporting of any adverse events following withdrawal of the study drug. Any participant who withdraws before completing treatment will be requested to return for an Early Termination Visit, at which time the procedures normally scheduled for the W16 visit will be conducted.


265 patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Male and female participants ≥18 years of age.
  • Able and willing to give informed consent and to comply with scheduled visits and trial procedures.
  • A diagnosis of DKD due to either T1DM or T2DM (diagnosed for ≥1 year)

On a stable anti-diabetic medication regimen for ≥4 months prior to randomization with a hemoglobin A1C (HbA1c) <9.5%.

  • Participants with T1DM may not be on any glucose lowering medications beyond insulin.
  • Participants with T2DM may be on more than 1 anti diabetic medication regimen (eg, SGLT2 inhibitor, insulin, or other anti-diabetic medication regimen).
  • HbA1c should have been performed within the last 4 months prior to randomization.
  • Participants must be on a stable dose of ACEi or ARB for ≥4 months prior to randomization and expected to remain stable for the 4-month treatment period.
  • Participants taking finerenone (not required), on a stable dose for ≥4 months prior to randomization.
  • Presence of albuminuria with a UACR >100 mg/g and <3000 mg/g at screening.

Exclusion criteria

Significant medical condition, that in the opinion of the Investigator will place the participant at risk during the study or that will confound the study endpoints.

Participants not fully vaccinated for Coronavirus Disease 2019 (COVID 19).

  • Participants will be considered fully vaccinated if they have received all recommended doses of a COVID-19 vaccine that has been authorized or approved by the United States Food and Drug Administration (FDA) or is listed for emergency use by the World Health Organization within 14 days prior to the first dose of the study drug.
  • Participants who have fully recovered from COVID 19 and have a negative COVID-19 test ≥14 days before screening are eligible.
  • Other causes of kidney disease that are not DKD (eg, lupus nephritis). Of note, hypertension is not an exclusion criteria.
  • Participants with an eGFR <30 ml/min/1.73m².
  • Participants who have had acute kidney injury (AKI) within the past 3 months, or have ever received dialysis.
  • Participants with a history of epilepsy or intracranial surgery.
  • Uncontrolled hypertension with measurements of systolic pressures >160 or diastolic measurements >100 at the Screening Visit.
  • Active substance abuse including inhaled or injection drugs in the year prior to screening.
  • Use of cannabis or cannabinoid containing compounds within 90 days prior to screening.
  • Pregnancy, planned pregnancy, potential for pregnancy or unwillingness to use effective birth control during the trial, as well as breast feeding.
  • Evidence of moderate to severe hepatic impairment as defined by Child's-Pugh B or C.

Subjects with a history of significant psychiatric disorder, including but not limited to:

  • Major depression within the last 2 years.
  • Any history of a suicide attempt or suicidal ideation.
  • Subjects with a history of other severe psychiatric disorders (eg, schizophrenia, bipolar disorder).
  • Score of the 9-question Patient Health Questionnaire (PHQ-9) ≥15 at baseline.
  • Current or active malignancy within the past 5 years, except for cancer in situ, or non-melanoma skin cancer such as basal cell or squamous cell carcinoma that has been completely resected.
  • QTc >500 msec at baseline.
  • Any chronic medications started or changed within the past 3 months or at risk of needing to be changed during the study.
  • Participants with a history of hyperthyroidism or other thyroid diseases.
  • Participants taking a strong inducer or inhibitor of cytochrome P450 3A4, 2D6 or 2C19 by screening. These medications are prohibited during the entire study duration.
  • Having taken any investigational compound within 30 days, or 5 half-lives of the drug, whichever is longer, before the Screening Visit.

Trial design

Primary purpose




Interventional model

Parallel Assignment


Triple Blind

265 participants in 3 patient groups, including a placebo group

INV 202 10 mg
Experimental group
INV-202 10 mg Arm
Drug: INV-202
INV-202 25 mg
Experimental group
INV-202 25 mg Arm
Drug: INV-202
Placebo Comparator group
Placebo Arm
Drug: Placebo

Trial contacts and locations



Central trial contact

Karine Lalonde, MSc; Glenn Crater, MD

Data sourced from

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems